Johnson & Johnson ’s Nipocalimab Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Spring House, Pa. (February 9, 2024)– Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for nipocalimab for the treatment of alloimmunizeda pregnant...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials